Released on = December 2, 2006, 6:46 am

Press Release Author = mark henry

Industry = Healthcare

Press Release Summary = Equipoise is the popular brand name for the veterinary
injectable steroid boldenoness undecylenate. It is a derivative of testosterone,
which exhibits strong anabolic and moderately androgenic properties. The
undecylenate ester greatly extends the activity of the drug (the undecylenate ester
is only one carbon atom longer than decanoate), so that clinically injections would
need to be repeated every three or four weeks. In the veterinary feild Equipoise is
most commonly used on horses, exhibiting a pronounced effect on lean bodyweight,
appetite and general disposition of the animal. As with all steroids, this compound
shows a marked ability for increasing red blood cell production. In recent years
this compound has become a favorite among athletes. Many consider it an ideal
replacement to Deca-Durabolin......


Press Release Body = Equipoise is the popular brand name for the veterinary injectable steroid boldenoness undecylenate. It is a derivative of testosterone,
which exhibits strong anabolic and moderately androgenic properties. The
undecylenate ester greatly extends the activity of the drug (the undecylenate ester
is only one carbon atom longer than decanoate), so that clinically injections would
need to be repeated every three or four weeks. In the veterinary feild Equipoise is
most commonly used on horses, exhibiting a pronounced effect on lean bodyweight,
appetite and general disposition of the animal. As with all steroids, this compound
shows a marked ability for increasing red blood cell production. In recent years
this compound has become a favorite among athletes. Many consider it an ideal
replacement to Deca-Durabolin.

The side effects of Equipoise are generally mild. The structure of boldenone does
allow it to convert into estrogen, but it does not have an extremely high affinity
to do so. If we look at aromatization studies, they suggest that its rate of
estrogen conversion should be about half that of testosterone's. Water retention
with this drug would therefore be slightly higher than that with Deca-Durabolin
(with an estimated 20% conversion), but much less than we would find with a stronger
compound as Testosterone. While there is still a chance of encountering an estrogen
related side effect as such when using Equipoise, problems are usually not
encountered at a moderate dosage level. Gynecomastia might become a problem, but
usually only with very sensitive individuals or (again) with those using higher
dosages. If estrogenic effects become a problem, the addition of Nolvadex should of
course make the cycle more tolerable. An anti-aromatase such as Arimidex, Femara, or
Amonasin would be a stronger option, however probably not necessary with such a mild
drug.

Although typically dosage related, Equipoise can also produce distinct androgenic
side effects. Oily skin, acne, increased aggression and hair loss are all possible
with this compound. Women find this drug quite comfortable, virilization symptoms
usually unheard of when taken at low doses. Boldenone does reduce to a more potent
androgen (dihydroboldenone) via the 5alpha reductase enzyme (which produces DHT from testosterone), however its affinity for this interaction in the human body is low to
nonexistent. Therefore the reductase inhibitor Proscar would not be of much use with
Equipoise, as it would be blocking what is at best an insignificant path of metabolism for the steroid. Although this drug is relatively mild, it still has a depressive effect on endogenous testosterone levels, therefore a proper post cycle therapy HCG and Clomid/Nolvadex is needed at the conclusion of each cycle to avoid a"crash". A waiting time of around 3 weeks is required before starting PCT, enabling enough of the drug to clear one's system to make PCT effective.

In order to maintain stable blood levels, Equipoise should be injected at least once
per week. It is most commonly used at a dosage of 400-600mg per week for men, 50-150 mg per week for women.

Equipoise is not a rapid mass builder, but will provide a slow but steady gain of
strength and quality muscle mass. The most positive effects of this drug are seen
when it is used for longer cycles, usually lasting at least 10 weeks in length. The
muscle gained should not be the smooth bulk seen with androgens, but instead a very
defined and solid look. Since water bloat is not contributing greatly to the
diameter of the muscle, much of the size gained on a cycle of Equipoise can be
retained after the drug has been discontinued. It is interesting to note that
structurally Equipoise and the classic bulking drug Dianabol are almost identical.
In the case of Equipoise the compound uses a l7beta ester (undecylenate), while
Dianabol is 17 alpha alkylated. Aside from that difference, the drugs are basically
the same. Of course they act quite differently in the body, which goes to show the
17-methylation effects more than just the oral efficancy of a steroid.

As discussed earlier, Equipoise is a very versatile compound. We can create a number
of drug combinations with it depending on the desired result. For mass, one may want
to stack it with Anadrol or an injectable testosterone. The result should be an
incredible gain of muscle size and strength, without the same intensity of side
effects if using the androgen (at a higher dose) alone. When used in a cutting
cycle, muscle hardness and density can be greatly improved when combining Equipoise
with a non-aromatizable steroid such as trenbolone acetate, Halotestin, or Winstrol.
For some however, even the low buildup of estrogen associated with this compound is
enough to relegate its use to bulking cycles only.

Equipoise is not an ideal steroid for the drug tested athlete however. This drug has
the tendency to produce detectable metabolites in the urine months after use, a
worry most commonly associated with Deca-Durabolin. This is of course due to the
high oil solubility of long chain esterified injectable steroids, a property which
enables the drug to remain deposited in fatty tissues for extended periods of time.
While this will reliably slow the release of steroid into the blood stream, it also
allows small residual amounts to remain present in the body far after the initial
injection. The release of stubborn stores of hormone would no doubt also be enhanced
around contest time, a period when the athlete drastically attempts to mobilize
unwanted body fat. If enough were used in the off-season, the athlete may actually
fail a drug screen for boldenone although many months may have past since the drug
was last injected.


Web Site = http://

Contact Details =